Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 0%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc. has reported a 41% quarter-over-quarter increase in NeXT Personal Dx volumes for Q4'25, exceeding market expectations and indicating strong momentum for the company's testing solutions. The recent acquisition of Medicare coverage for the NeXT Personal MRD test, particularly in breast cancer, coupled with expected marketing acceleration by commercial partner Tempus, presents significant growth opportunities in the near future. Additionally, the company's focus on distinguishing its tests in early cancer recurrence detection, evidenced by the performance data showing 40% of ctDNA positive samples in the 1-100ppm detection range, underscores the value proposition of its offerings in a rapidly evolving market.

Bears say

Personalis Inc has provided a downward revision of its revenue guidance for 2025, projecting a decrease to $68 million-$73 million from a prior estimate of $70 million-$80 million, which highlights a concerning year-over-year decline in pharmaceutical services revenue partially due to the conclusion of Moderna’s Phase III melanoma trial. Furthermore, the company has encountered logistical challenges affecting its global sample processing, which may hinder its ability to capitalize on market opportunities amidst a general slowdown in the biopharmaceutical sector. Lastly, concerns about significant losses incurred since inception, compounded by existing debt, raise doubts about Personalis’s capacity to achieve long-term profitability and revenue sustainability.

Personalis Inc (PSNL) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 0% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.